Disease on EC 1.14.11.4 - procollagen-lysine 5-dioxygenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma of Lung
A collagen glucosyltransferase drives lung adenocarcinoma progression in mice.
High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma.
Lysyl hydroxylases are transcription targets for GATA3 driving lung cancer cell metastasis.
PCAF-mediated acetylation of transcriptional factor HOXB9 suppresses lung adenocarcinoma progression by targeting oncogenic protein JMJD6.
PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.
Alkaptonuria
In vitro inhibition of chick embryo lysyl hydroxylase by homogentisic acid. A proposed connective tissue defect in alkaptonuria.
Alopecia
Minoxidil Cannot Be Used To Target Lysyl Hydroxylases during Postnatal Mouse Lung Development: A Cautionary Note.
Alzheimer Disease
Gene expression profiling of peripheral blood leukocytes shows consistent longitudinal downregulation of TOMM40 and upregulation of KIR2DL5A, PLOD1, and SLC2A8 among fast progressors in early Alzheimer's disease.
Aortic Rupture
A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis.
Arteriovenous Malformations
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) expression in brain arteriovenous malformations (bAVM) and its association with bAVM size.
Azoospermia
Prediction of 3D Protein Structure Based on The Mutation of AKAP3 and PLOD3 Genes in The Case of Non-Obstructive Azoospermia.
Biliary Tract Neoplasms
ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Breast Neoplasms
Adipocyte-derived IL-6 and leptin promote breast Cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression.
Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
Correlation between procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 and breast cancer.
DT-13 suppresses breast cancer metastasis by modulating PLOD2 in the adipocytes microenvironment.
Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
Identification of disease-promoting stromal components by comparative proteomic and transcriptomic profiling of canine mammary tumors using laser-capture microdissected FFPE tissue.
JMJD6 induces HOTAIR, an oncogenic lincRNA, by physically interacting with its proximal promoter.
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
JMJD6 Licenses ER?-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex.
JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity.
LncRNA ZFPM2-AS1 aggravates the malignant development of breast cancer via upregulating JMJD6.
Procollagen Lysyl Hydroxylase 2 is Essential for Breast Cancer Metastasis.
Role of JMJD6 in Breast Tumourigenesis.
The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling.
Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression.
Bronchopulmonary Dysplasia
Deregulation of the lysyl hydroxylase matrix cross-linking system in experimental and clinical bronchopulmonary dysplasia.
Minoxidil Cannot Be Used To Target Lysyl Hydroxylases during Postnatal Mouse Lung Development: A Cautionary Note.
Bursitis
The roles of Tenascin C and Fibronectin 1 in adhesive capsulitis: a pilot gene expression study.
Carcinogenesis
Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma.
Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.
Bifunctional Enzyme JMJD6 Contributes to Multiple Disease Pathogenesis: New Twist on the Old Story.
Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties.
High Expression of PLOD1 Drives Tumorigenesis and Affects Clinical Outcome in Gastrointestinal Carcinoma.
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
JMJD6 Licenses ER?-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex.
JMJD6 Promotes Colon Carcinogenesis through Negative Regulation of p53 by Hydroxylation.
JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.
JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component.
Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.
Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression.
MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/?-catenin pathway in non-small cell lung cancer.
PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma.
PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer.
Protein arginine methylation/demethylation and cancer.
Role of JMJD6 in Breast Tumourigenesis.
The Collagen-Modifying Enzyme PLOD2 Is Induced and Required during L1-Mediated Colon Cancer Progression.
The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Carcinoma
Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma.
Characterization of a cancer-associated Epstein-Barr virus EBNA1 variant reveals a novel interaction with PLOD1 and PLOD3.
Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties.
Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
High Expression of PLOD1 Drives Tumorigenesis and Affects Clinical Outcome in Gastrointestinal Carcinoma.
Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-?B signaling.
Involvement of microRNA-124 in biological behaviors of laryngeal carcinoma via PLOD2 signaling pathway.
Jumonji domain-containing protein 6 functions as a marker of head and neck squamous cell carcinoma at advanced stage with no effect on prognosis.
Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression.
Lysyl hydroxylase 2-induced collagen cross-link switching promotes metastasis in head and neck squamous cell carcinomas.
PLOD2 Is Essential to Functional Activation of Integrin ?1 for Invasion/Metastasis in Head and Neck Squamous Cell Carcinomas.
Procollagen-lysine, 2-oxoglutarate 5-dioxygenases 1, 2, and 3 are potential prognostic indicators in patients with clear cell renal cell carcinoma.
Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma.
Targeted Demethylation of the PLOD2 mRNA Inhibits the Proliferation and Migration of Renal Cell Carcinoma.
[Expression of PLOD2 in esophageal squamous cell carcinoma and its correlation with invasion and metastasis].
Carcinoma, Hepatocellular
Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.
JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.
PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection.
Carcinoma, Non-Small-Cell Lung
MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/?-catenin pathway in non-small cell lung cancer.
[Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells].
Carcinoma, Renal Cell
Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression.
Procollagen-lysine, 2-oxoglutarate 5-dioxygenases 1, 2, and 3 are potential prognostic indicators in patients with clear cell renal cell carcinoma.
Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma.
Targeted Demethylation of the PLOD2 mRNA Inhibits the Proliferation and Migration of Renal Cell Carcinoma.
Carcinoma, Squamous Cell
Jumonji domain-containing protein 6 functions as a marker of head and neck squamous cell carcinoma at advanced stage with no effect on prognosis.
Lysyl hydroxylase 2-induced collagen cross-link switching promotes metastasis in head and neck squamous cell carcinomas.
PLOD2 Is Essential to Functional Activation of Integrin ?1 for Invasion/Metastasis in Head and Neck Squamous Cell Carcinomas.
Cataract
Lysyl hydroxylase 3 is required for normal lens capsule formation and maintenance of lens epithelium integrity and fate.
Choriocarcinoma
Jumonji Domain Containing Protein 6: A Novel Oxygen Sensor in the Human Placenta.
Cleft Lip
New insights in collagen turnover in orofacial cleft patients.
Cleft Palate
New insights in collagen turnover in orofacial cleft patients.
Collagen Diseases
Molecular defects in the Ehlers-Danlos syndrome.
Colonic Neoplasms
?-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells.
High Expression of PLOD1 Drives Tumorigenesis and Affects Clinical Outcome in Gastrointestinal Carcinoma.
JMJD6 Promotes Colon Carcinogenesis through Negative Regulation of p53 by Hydroxylation.
Livin promotes colon cancer progression by regulation of H2A.XY39ph via JMJD6.
PLOD3 Is Associated with Immune Cell Infiltration and Genomic Instability in Colon Adenocarcinoma.
Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4.
The Collagen-Modifying Enzyme PLOD2 Is Induced and Required during L1-Mediated Colon Cancer Progression.
Colorectal Neoplasms
High Expression of PLOD1 Drives Tumorigenesis and Affects Clinical Outcome in Gastrointestinal Carcinoma.
Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-?B signaling.
N-glycoprotein analysis discovers new up-regulated glycoproteins in colorectal cancer tissue.
PLOD2 promotes aerobic glycolysis and cell progression in colorectal cancer by upregulating HK2.
Connective Tissue Diseases
FKBP65-dependent peptidyl-prolyl isomerase activity potentiates the lysyl hydroxylase 2-driven collagen cross-link switch.
Contracture
A novel homozygous 5bp deletion in FKBP10 causes clinically Bruck syndrome in an Indonesian patient.
Bruck syndrome 2 variant lacking congenital contractures and involving a novel compound heterozygous PLOD2 mutation.
Expanding the Clinical Spectrum of Phenotypes Caused by Pathogenic Variants in PLOD2.
Mutations in FKBP10 cause recessive osteogenesis imperfecta and type 1 bruck syndrome.
Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen.
Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome-Osteogenesis imperfecta phenotypic spectrum.
Orthopedic Manifestations of Bruck Syndrome: A Case Series with Intermediate to Long-term Follow-Up.
Phenotypic and molecular characterization of Bruck syndrome (osteogenesis imperfecta with contractures of the large joints) caused by a recessive mutation in PLOD2.
Cutis Laxa
Defects in the biochemistry of collagen in diseases of connective tissue.
Diabetes Mellitus, Experimental
Glomerular protocollagen lysyl-hydroxylase activity in streptozotocin diabetes.
The effect of alloxan diabetes on prolyl and lysyl hydroxylase activity in uninflamed and inflamed rat gingiva.
Diabetes Mellitus, Type 1
Thymic epithelial cell-specific deletion of Jmjd6 reduces Aire protein expression and exacerbates disease development in a mouse model of autoimmune diabetes.
Diabetes, Gestational
Jumonji domain-containing protein 6 protein and its role in cancer.
Diabetic Nephropathies
Effect of diabetes and insulin on rat renal glomerular protocollagen hydroxylase activities.
DNA Virus Infections
Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses.
Ehlers-Danlos Syndrome
A case of Ehlers-Danlos syndrome type VIA with a novel PLOD1 gene mutation.
A common duplication in the lysyl hydroxylase gene of patients with Ehlers Danlos syndrome type VI results in preferential stimulation of lysyl hydroxylase activity and mRNA by hydralazine.
A compound heterozygote patient with Ehlers-Danlos syndrome type VI has a deletion in one allele and a splicing defect in the other allele of the lysyl hydroxylase gene.
A homozygous stop codon in the lysyl hydroxylase gene in two siblings with Ehlers-Danlos syndrome type VI.
A large duplication in the gene for lysyl hydroxylase accounts for the type VI variant of Ehlers-Danlos syndrome in two siblings.
A new Ehlers-Danlos syndrome with craniofacial characteristics, multiple congenital contractures, progressive joint and skin laxity, and multisystem fragility-related manifestations.
A nonsense codon of exon 14 reduces lysyl hydroxylase mRNA and leads to aberrant RNA splicing in a patient with Ehlers-Danlos syndrome type VI.
A novel mutation in the lysyl hydroxylase 1 gene causes decreased lysyl hydroxylase activity in an Ehlers-Danlos VIA patient.
A null-mutated lysyl hydroxylase gene in a compound heterozygote British patient with Ehlers-Danlos syndrome type VI.
A patient with Ehlers-Danlos syndrome type VI is a compound heterozygote for mutations in the lysyl hydroxylase gene.
A patient with Ehlers-Danlos syndrome type VI is homozygous for a premature termination codon in exon 14 of the lysyl hydroxylase 1 gene.
A splice-site mutation that induces exon skipping and reduction in lysyl hydroxylase mRNA levels but does not create a nonsense codon in Ehlers-Danlos syndrome type VI.
A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis.
Adenoviral gene transfer restores lysyl hydroxylase activity in type VI Ehlers-Danlos syndrome.
Alu-Alu recombination results in a duplication of seven exons in the lysyl hydroxylase gene in a patient with the type VI variant of Ehlers-Danlos syndrome.
An Ehlers-Danlos syndrome type VIA patient with cystic malformations of the meninges.
An in vitro model to evaluate the properties of matrices produced by fibroblasts from osteogenesis imperfecta and Ehlers-Danlos Syndrome patients.
Biochemical characterization of variants of the Ehlers-Danlos syndrome type VI.
Cloning and characterization of a third human lysyl hydroxylase isoform.
Collagen maturation defects in Ehlers-Danlos keratopathy.
Defects in the biochemistry of collagen in diseases of connective tissue.
Deletion of cysteine 369 in lysyl hydroxylase 1 eliminates enzyme activity and causes Ehlers-Danlos syndrome type VI.
Delineation of dermatan 4-O-sulfotransferase 1 deficient Ehlers-Danlos syndrome: Observation of two additional patients and comprehensive review of 20 reported patients.
Duplication of seven exons in the lysyl hydroxylase gene is associated with longer forms of a repetitive sequence within the gene and is a common cause for the type VI variant of Ehlers-Danlos syndrome.
Ehlers Danlos syndrome, kyphoscoliotic type due to Lysyl Hydroxylase 1 deficiency in two children without congenital or early onset kyphoscoliosis.
Ehlers-Danlos syndrome in two siblings with deficient lysyl hydroxylase activity in cultured skin fibroblasts but only mild hydroxylysine deficit in skin.
Ehlers-Danlos syndrome type VI results from a nonsense mutation and a splice site-mediated exon-skipping mutation in the lysyl hydroxylase gene.
Ehlers-Danlos syndrome type VI with normal lysyl hydroxylase activity cannot be explained by a defect in cellular uptake of ascorbic acid.
Ehlers-Danlos syndrome type VI: clinical manifestations of collagen lysyl hydroxylase deficiency.
Ehlers-Danlos syndrome type VI: collagen type specificity of defective lysyl hydroxylation in various tissues.
Ehlers-Danlos syndrome type VI: lysyl hydroxylase deficiency due to a novel point mutation (W612C).
Genotyping and prenatal assessment of collagen lysyl hydroxylase deficiency in a family with Ehlers-Danlos syndrome type VI.
Heterogeneous basis of the type VIB form of Ehlers-Danlos syndrome (EDS VIB) that is unrelated to decreased collagen lysyl hydroxylation.
Human lysyl hydroxylase: purification to homogeneity, partial characterization and comparison of catalytic properties with those of a mutant enzyme from Ehlers-Danlos syndrome type VI fibroblasts.
Joint and skin laxity with Dandy-Walker malformation and contractures: a distinct recessive syndrome?
Mutation analysis of the PLOD1 gene: an efficient multistep approach to the molecular diagnosis of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA).
Mutational analysis of the lysyl hydroxylase 1 gene (PLOD) in six unrelated patients with Ehlers-Danlos syndrome type VI: prenatal exclusion of this disorder in one family.
Mutations in the lysyl hydroxylase 1 gene that result in enzyme deficiency and the clinical phenotype of Ehlers-Danlos syndrome type VI.
Nevo syndrome is allelic to the kyphoscoliotic type of the Ehlers-Danlos syndrome (EDS VIA).
Novel human pathological mutations. Gene symbol: PLOD1. Disease: Ehlers-Danlos syndrome type VIA, kyphoscoliotic type.
Ocular Ehlers-Danlos syndrome with normal lysyl hydroxylase activity.
Phenotypic variability of the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA): clinical, molecular and biochemical delineation.
Preferential hydroxylation of type IV collagen by lysyl hydroxylase from Ehlers-Danlos syndrome type VI fibroblasts.
Prenatal exclusion of Ehlers-Danlos syndrome type VI by mutational analysis.
Structure and expression of the human lysyl hydroxylase gene (PLOD): introns 9 and 16 contain Alu sequences at the sites of recombination in Ehlers-Danlos syndrome type VI patients.
The Ehlers-Danlos syndromes.
The first case report of Kyphoscoliotic Ehlers-Danlos syndrome of chinese origin with a novel PLOD1 gene mutation.
The kyphoscoliotic type of Ehlers-Danlos syndrome (type VI): differential effects on the hydroxylation of lysine in collagens I and II revealed by analysis of cross-linked telopeptides from urine.
The mRNA and the activity of lysyl hydroxylase are up-regulated by the administration of ascorbate and hydralazine to human skin fibroblasts from a patient with Ehlers-Danlos syndrome type VI.
Transcriptome Profiling of Primary Skin Fibroblasts Reveal Distinct Molecular Features Between PLOD1- and FKBP14-Kyphoscoliotic Ehlers-Danlos Syndrome.
Two novel variants in PLOD1 causing hydrocephalus in female newborn with kyphoscoliotic Ehlers-Danlos syndrome.
[Ehlers-Danlos syndrome]
[The biochemistry of collagen and the locomotor apparatus. Hereditary diseases of connective tissue and rheumatologic diseases (part 2)]
Endometrial Neoplasms
Hypoxia-induced PLOD2 regulates invasion and epithelial-mesenchymal transition in endometrial carcinoma cells.
Epidermolysis Bullosa Dystrophica
Lysyl Hydroxylase 3 Localizes to Epidermal Basement Membrane and Is Reduced in Patients with Recessive Dystrophic Epidermolysis Bullosa.
Esophageal Squamous Cell Carcinoma
Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma.
Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-?B signaling.
[Expression of PLOD2 in esophageal squamous cell carcinoma and its correlation with invasion and metastasis].
Foot-and-Mouth Disease
Analysis of Amino Acid Mutations of the Foot-and-Mouth Disease Virus Serotype O Using both Heparan Sulfate and JMJD6 Receptors.
Bifunctional Enzyme JMJD6 Contributes to Multiple Disease Pathogenesis: New Twist on the Old Story.
Jumonji domain-containing protein 6 protein and its role in cancer.
Gastrointestinal Neoplasms
High Expression of PLOD1 Drives Tumorigenesis and Affects Clinical Outcome in Gastrointestinal Carcinoma.
Genetic Diseases, Inborn
Warmblood Fragile Foal Syndrome causative single nucleotide polymorphism frequency in Warmblood horses in Brazil.
Glioblastoma
Histology-based expression profiling yields novel prognostic markers in human glioblastoma.
Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-?B signaling.
Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas.
Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion.
Transcription Elongation Factors Are Potential Targets in Glioblastoma.
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma.
Glioma
Correction: Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion.
Expression and Prognostic Role of PLOD1 in Malignant Glioma.
Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-?B signaling.
Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma.
Inhibition of JMJD6 expression reduces the proliferation, migration and invasion of neuroglioma stem cells.
Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas.
Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion.
The relationship between PLOD1 expression level and glioma prognosis investigated using public databases.
Hearing Loss
A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis.
FKBP14 kyphoscoliotic Ehlers-Danlos Syndrome in adolescent patient: the first Colombian report.
Hepatitis B, Chronic
Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection.
Hepatitis C
Jumonji domain-containing protein 6 protein and its role in cancer.
Hydrocephalus
Two novel variants in PLOD1 causing hydrocephalus in female newborn with kyphoscoliotic Ehlers-Danlos syndrome.
Hyperalgesia
Normalizing JMJD6 Expression in Rat Spinal Dorsal Horn Alleviates Hyperalgesia Following Chronic Constriction Injury.
Hyperglycemia
Glomerular protocollagen lysyl-hydroxylase activity in streptozotocin diabetes.
Hypertension
Identifying multiple causative genes at a single GWAS locus.
Minoxidil Cannot Be Used To Target Lysyl Hydroxylases during Postnatal Mouse Lung Development: A Cautionary Note.
Infections
Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection.
Iron Deficiencies
JMJD6 Dysfunction Due to Iron Deficiency in Preeclampsia Disrupts Fibronectin Homeostasis Resulting in Diminished Trophoblast Migration.
Joint Instability
The first case report of Kyphoscoliotic Ehlers-Danlos syndrome of chinese origin with a novel PLOD1 gene mutation.
Kidney Neoplasms
Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.
The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma.
Laryngeal Neoplasms
PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics.
Liver Cirrhosis
A twenty gene-based gene set variation score reflects the pathological progression from cirrhosis to hepatocellular carcinoma.
Identification of differentially expressed genes in hepatic HepG2 cells treated with acetaminophen using suppression subtractive hybridization.
Lung Neoplasms
MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/?-catenin pathway in non-small cell lung cancer.
PLOD3 promotes lung metastasis via regulation of STAT3.
PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling pathway.
[Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells].
Lymphatic Metastasis
Correlation between procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 and breast cancer.
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
[Expression of PLOD2 in esophageal squamous cell carcinoma and its correlation with invasion and metastasis].
[Upregulation of PLOD2 promotes invasion and metastasis of osteosarcoma cells].
Melanoma
JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component.
Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression.
Mouth Neoplasms
Bifunctional Enzyme JMJD6 Contributes to Multiple Disease Pathogenesis: New Twist on the Old Story.
Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties.
Muscle Hypotonia
The first case report of Kyphoscoliotic Ehlers-Danlos syndrome of chinese origin with a novel PLOD1 gene mutation.
Transcriptome Profiling of Primary Skin Fibroblasts Reveal Distinct Molecular Features Between PLOD1- and FKBP14-Kyphoscoliotic Ehlers-Danlos Syndrome.
Muscular Diseases
A substrate preference for the rough endoplasmic reticulum resident protein FKBP22 during collagen biosynthesis.
FKBP14 kyphoscoliotic Ehlers-Danlos Syndrome in adolescent patient: the first Colombian report.
Myopia
A DNA pooling-based case-control study of myopia candidate genes COL11A1, COL18A1, FBN1, and PLOD1 in a Chinese population.
Neoplasm Metastasis
A collagen glucosyltransferase drives lung adenocarcinoma progression in mice.
A feedback loop between hypoxia and matrix stress relaxation increases oxygen-axis migration and metastasis in sarcoma.
Adipocyte-derived IL-6 and leptin promote breast Cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression.
Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma.
Correlation between procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 and breast cancer.
DT-13 suppresses breast cancer metastasis by modulating PLOD2 in the adipocytes microenvironment.
Global secretome analysis identifies novel mediators of bone metastasis.
Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma.
Hypoxia and TGF-?1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation.
Hypoxia-Dependent Modification of Collagen Networks Promotes Sarcoma Metastasis.
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
JMJD6 induces HOTAIR, an oncogenic lincRNA, by physically interacting with its proximal promoter.
Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma.
Lysyl hydroxylase 2-induced collagen cross-link switching promotes metastasis in head and neck squamous cell carcinomas.
Lysyl hydroxylases are transcription targets for GATA3 driving lung cancer cell metastasis.
Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas.
PLOD1 Is a Prognostic Biomarker and Mediator of Proliferation and Invasion in Osteosarcoma.
PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma.
PLOD2 Is Essential to Functional Activation of Integrin ?1 for Invasion/Metastasis in Head and Neck Squamous Cell Carcinomas.
PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.
PLOD2-driven IL-6/STAT3 signaling promotes the invasion and metastasis of oral squamous cell carcinoma via activation of integrin ?1.
PLOD3 promotes lung metastasis via regulation of STAT3.
Procollagen Lysyl Hydroxylase 2 is Essential for Breast Cancer Metastasis.
Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma.
The Collagen-Modifying Enzyme PLOD2 Is Induced and Required during L1-Mediated Colon Cancer Progression.
The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
The relationship between PLOD1 expression level and glioma prognosis investigated using public databases.
Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling.
[Expression of PLOD2 in esophageal squamous cell carcinoma and its correlation with invasion and metastasis].
[Upregulation of PLOD2 promotes invasion and metastasis of osteosarcoma cells].
Neoplasms
111 ALTERATIONS IN BOVINE ENDOMETRIAL MESSENGER AND micro RNA EXPRESSION PROFILE DUE TO CLINICAL ENDOMETRITIS.
A collagen glucosyltransferase drives lung adenocarcinoma progression in mice.
A five-gene signature is a prognostic biomarker in pan-cancer and related with immunologically associated extracellular matrix.
Aberrant Collagen Cross-linking in Human Oral Squamous Cell Carcinoma.
Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target.
Adipocyte-derived IL-6 and leptin promote breast Cancer metastasis via upregulation of Lysyl Hydroxylase-2 expression.
Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities.
ASO Author Reflections: Hypoxia-Induced PLOD2 Is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Association analysis of bone mineral density and single nucleotide polymorphisms in two candidate genes on chromosome 1p36.
Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.
Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma.
Characterization of a cancer-associated Epstein-Barr virus EBNA1 variant reveals a novel interaction with PLOD1 and PLOD3.
Comparative study of the haplotype structure and linkage disequilibrium of chromosome 1p36.2 region in the Korean and Japanese populations.
Correlation between procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 and breast cancer.
DT-13 suppresses breast cancer metastasis by modulating PLOD2 in the adipocytes microenvironment.
Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties.
Expression and Prognostic Role of PLOD1 in Malignant Glioma.
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance.
Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer.
High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma.
High Expression of PLOD1 Drives Tumorigenesis and Affects Clinical Outcome in Gastrointestinal Carcinoma.
Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma.
Hypoxia and TGF-?1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation.
Hypoxia-Dependent Modification of Collagen Networks Promotes Sarcoma Metastasis.
Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-?B signaling.
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Hypoxia-induced PLOD2 regulates invasion and epithelial-mesenchymal transition in endometrial carcinoma cells.
Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility.
Identification of PLOD Family Genes as Novel Prognostic Biomarkers for Hepatocellular Carcinoma.
In Silico Discovery of JMJD6 Inhibitors for Cancer Treatment.
Inhibition of JMJD6 expression reduces the proliferation, migration and invasion of neuroglioma stem cells.
JMJD6 induces HOTAIR, an oncogenic lincRNA, by physically interacting with its proximal promoter.
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
JMJD6 Promotes Colon Carcinogenesis through Negative Regulation of p53 by Hydroxylation.
Jmjd6, a JmjC Dioxygenase with Many Interaction Partners and Pleiotropic Functions.
Jumonji Domain Containing Protein 6: A Novel Oxygen Sensor in the Human Placenta.
Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.
Jumonji domain-containing protein 6 protein and its role in cancer.
Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression.
KRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and is Resilient to TGF?1 Activation.
Livin promotes colon cancer progression by regulation of H2A.XY39ph via JMJD6.
LncRNA ZFPM2-AS1 aggravates the malignant development of breast cancer via upregulating JMJD6.
LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer.
Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma.
Lysyl Hydroxylase 2 Is Secreted by Tumor Cells and Can Modify Collagen in the Extracellular Space.
MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/?-catenin pathway in non-small cell lung cancer.
Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas.
PLOD1 Is a Prognostic Biomarker and Mediator of Proliferation and Invasion in Osteosarcoma.
PLOD1 promotes cell growth and aerobic glycolysis by regulating the SOX9/PI3K/Akt/mTOR signaling pathway in gastric cancer.
PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma.
PLOD2 contributes to drug resistance in laryngeal cancer by promoting cancer stem cell-like characteristics.
PLOD2 in cancer research.
PLOD2 increases resistance of gastric cancer cells to 5-fluorouracil by upregulating BCRP and inhibiting apoptosis.
PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer.
PLOD2 Is Essential to Functional Activation of Integrin ?1 for Invasion/Metastasis in Head and Neck Squamous Cell Carcinomas.
PLOD2 promotes aerobic glycolysis and cell progression in colorectal cancer by upregulating HK2.
PLOD2 regulated by transcription factor FOXA1 promotes metastasis in NSCLC.
PLOD3 Is Associated with Immune Cell Infiltration and Genomic Instability in Colon Adenocarcinoma.
PLOD3 is Upregulated in Gastric Cancer and Correlated with Clinicopathologic Characteristics.
PLOD3 promotes lung metastasis via regulation of STAT3.
PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling pathway.
PLODs are overexpressed in ovarian cancer and are associated with gap junctions via connexin 43.
Procollagen Lysyl Hydroxylase 2 is Essential for Breast Cancer Metastasis.
Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 promotes hypoxia-induced glioma migration and invasion.
Prognostic and therapeutic implications of extracellular matrix associated gene signature in renal clear cell carcinoma.
Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression.
Role of JMJD6 in Breast Tumourigenesis.
Targeted Demethylation of the PLOD2 mRNA Inhibits the Proliferation and Migration of Renal Cell Carcinoma.
The Collagen-Modifying Enzyme PLOD2 Is Induced and Required during L1-Mediated Colon Cancer Progression.
The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
The potential underlying mechanism of the leukemia caused by MLL-fusion and potential treatments.
The relationship between PLOD1 expression level and glioma prognosis investigated using public databases.
Tumor-secreted PAI-1 promotes breast cancer metastasis via the induction of adipocyte-derived collagen remodeling.
Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression.
Understanding the molecular mechanism associated with reversal of oral submucous fibrosis targeting hydroxylysine aldehyde-derived collagen cross-links.
[Expression of PLOD2 in esophageal squamous cell carcinoma and its correlation with invasion and metastasis].
[Upregulation of PLOD2 promotes invasion and metastasis of osteosarcoma cells].
Neuralgia
JMJD6 exerts function in neuropathic pain by regulating NF??B following peripheral nerve injury in rats.
Jumonji domain-containing protein 6 protein and its role in cancer.
Normalizing JMJD6 Expression in Rat Spinal Dorsal Horn Alleviates Hyperalgesia Following Chronic Constriction Injury.
[Wnt3a signaling pathway plays a role in neuropathic pain through epigenetic modification of JMJD6].
Neuroblastoma
JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.
Osteogenesis Imperfecta
An in vitro model to evaluate the properties of matrices produced by fibroblasts from osteogenesis imperfecta and Ehlers-Danlos Syndrome patients.
Case Report: Exome Sequencing Identified a Novel Compound Heterozygous Variation in PLOD2 Causing Bruck Syndrome Type 2.
Defects in the biochemistry of collagen in diseases of connective tissue.
Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome-Osteogenesis imperfecta phenotypic spectrum.
Phenomics-Based Quantification of CRISPR-Induced Mosaicism in Zebrafish.
Osteoporosis
Association of PLOD1 polymorphisms with bone mineral density in a population-based study of women from the UK.
Osteosarcoma
JMJD6-STAT3Y705ph axis promotes autophagy in osteosarcoma cancer cells by regulating ATG.
PLOD1 Is a Prognostic Biomarker and Mediator of Proliferation and Invasion in Osteosarcoma.
PLOD1 promotes cell growth and aerobic glycolysis by regulating the SOX9/PI3K/Akt/mTOR signaling pathway in gastric cancer.
PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma.
[Upregulation of PLOD2 promotes invasion and metastasis of osteosarcoma cells].
Ovarian Neoplasms
COLGALT2 is overexpressed in ovarian cancer and interacts with PLOD3.
Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.
PLODs are overexpressed in ovarian cancer and are associated with gap junctions via connexin 43.
Pancreatic Neoplasms
Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility.
Peripheral Nerve Injuries
JMJD6 exerts function in neuropathic pain by regulating NF??B following peripheral nerve injury in rats.
Pre-Eclampsia
Compromised JMJD6 histone demethylase activity impacts on VHL gene repression in preeclampsia.
JMJD6 Dysfunction Due to Iron Deficiency in Preeclampsia Disrupts Fibronectin Homeostasis Resulting in Diminished Trophoblast Migration.
Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production.
Jumonji Domain Containing Protein 6: A Novel Oxygen Sensor in the Human Placenta.
Premature Birth
Minoxidil Cannot Be Used To Target Lysyl Hydroxylases during Postnatal Mouse Lung Development: A Cautionary Note.
procollagen c-endopeptidase deficiency
[The biochemistry of collagen and the locomotor apparatus. Hereditary diseases of connective tissue and rheumatologic diseases (part 2)]
procollagen-lysine 5-dioxygenase deficiency
A new Ehlers-Danlos syndrome with craniofacial characteristics, multiple congenital contractures, progressive joint and skin laxity, and multisystem fragility-related manifestations.
Defects in the biochemistry of collagen in diseases of connective tissue.
Delineation of dermatan 4-O-sulfotransferase 1 deficient Ehlers-Danlos syndrome: Observation of two additional patients and comprehensive review of 20 reported patients.
Ehlers Danlos syndrome, kyphoscoliotic type due to Lysyl Hydroxylase 1 deficiency in two children without congenital or early onset kyphoscoliosis.
Ehlers-Danlos syndrome type VI: clinical manifestations of collagen lysyl hydroxylase deficiency.
Ehlers-Danlos syndrome type VI: lysyl hydroxylase deficiency due to a novel point mutation (W612C).
Ehlers-Danlos syndrome type VIB with characteristic facies, decreased curvatures of the spinal column, and joint contractures in two unrelated girls.
Genotyping and prenatal assessment of collagen lysyl hydroxylase deficiency in a family with Ehlers-Danlos syndrome type VI.
Inherited human collagen lysyl hydroxylase deficiency: ascorbic acid response.
Intronic regulation of Aire expression by Jmjd6 for self-tolerance induction in the thymus.
JMJD6 modulates DNA damage response through downregulating H4K16ac independently of its enzymatic activity.
Joint and skin laxity with Dandy-Walker malformation and contractures: a distinct recessive syndrome?
Loss-of-function mutations of CHST14 in a new type of Ehlers-Danlos syndrome.
Two novel variants in PLOD1 causing hydrocephalus in female newborn with kyphoscoliotic Ehlers-Danlos syndrome.
Prostatic Neoplasms
Gene Regulation Network Analysis on Human Prostate Orthografts Highlights a Potential Role for the JMJD6 Regulon in Clinical Prostate Cancer.
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
Pulmonary Disease, Chronic Obstructive
PLOD3 Is Associated with Immune Cell Infiltration and Genomic Instability in Colon Adenocarcinoma.
Pulmonary Fibrosis
Lysyl hydroxylase 3 increases collagen deposition and promotes pulmonary fibrosis by activating TGF?1/Smad3 and Wnt/?-catenin pathways.
Lysyl Hydroxylase Inhibition by Minoxidil Blocks Collagen Deposition and Prevents Pulmonary Fibrosis via TGF-??/Smad3 Signaling Pathway.
RNA Virus Infections
JMJD6 negatively regulates cytosolic RNA induced antiviral signaling by recruiting RNF5 to promote activated IRF3 K48 ubiquitination.
Sarcoma
A feedback loop between hypoxia and matrix stress relaxation increases oxygen-axis migration and metastasis in sarcoma.
Catalytic properties of lysyl hydroxylase from cells synthesizing genetically different collagen types.
Hypoxia-Dependent Modification of Collagen Networks Promotes Sarcoma Metastasis.
Scleroderma, Systemic
Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis.
Scoliosis
Ehlers Danlos syndrome, kyphoscoliotic type due to Lysyl Hydroxylase 1 deficiency in two children without congenital or early onset kyphoscoliosis.
Shoulder Dislocation
Expression analysis of genes involved in collagen cross-linking and its regulation in traumatic anterior shoulder instability.
Squamous Cell Carcinoma of Head and Neck
Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties.
Jumonji domain-containing protein 6 functions as a marker of head and neck squamous cell carcinoma at advanced stage with no effect on prognosis.
Lysyl hydroxylase 2-induced collagen cross-link switching promotes metastasis in head and neck squamous cell carcinomas.
PLOD2 Is Essential to Functional Activation of Integrin ?1 for Invasion/Metastasis in Head and Neck Squamous Cell Carcinomas.
Starvation
Verteporfin as a Medical Treatment in Peyronie's Disease.
Stomach Neoplasms
High Expression of PLOD1 Drives Tumorigenesis and Affects Clinical Outcome in Gastrointestinal Carcinoma.
Hypoxia-induced PLOD1 overexpression contributes to the malignant phenotype of glioblastoma via NF-?B signaling.
PLOD1 promotes cell growth and aerobic glycolysis by regulating the SOX9/PI3K/Akt/mTOR signaling pathway in gastric cancer.
PLOD2 as a potential regulator of peritoneal dissemination in gastric cancer.
PLOD2 increases resistance of gastric cancer cells to 5-fluorouracil by upregulating BCRP and inhibiting apoptosis.
PLOD3 is Upregulated in Gastric Cancer and Correlated with Clinicopathologic Characteristics.
Triple Negative Breast Neoplasms
Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity.
type ii protein arginine methyltransferase deficiency
PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Urinary Bladder Neoplasms
Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target.
PLOD1 promotes cell growth and aerobic glycolysis by regulating the SOX9/PI3K/Akt/mTOR signaling pathway in gastric cancer.
Tumour-suppressive miRNA-26a-5p and miR-26b-5p inhibit cell aggressiveness by regulating PLOD2 in bladder cancer.
Uterine Cervical Neoplasms
Hypoxia and TGF-?1 induced PLOD2 expression improve the migration and invasion of cervical cancer cells by promoting epithelial-to-mesenchymal transition (EMT) and focal adhesion formation.
PLOD2 Is a Potent Prognostic Marker and Associates with Immune Infiltration in Cervical Cancer.
Vesicular Stomatitis
JMJD6 negatively regulates cytosolic RNA induced antiviral signaling by recruiting RNF5 to promote activated IRF3 K48 ubiquitination.